FDG-PET/CT Technical Committee Face-to-Face meeting in conjunction with SNM, Toronto Sunday, June 14, 2009

Attendees:

Richard Frank, MD, PhD (Co-Chair) Ronald Boellaard, PhD Andrew Buckler, MS Paul Christian Patricia Cole, PhD, MD Paul Kinahan, PhD Paul Marsden Ling Shao, PhD Jeffrey Yap, PhD Brian Zimmerman, PhD

RSNA

Susan Anderson

Agenda (Dr. Frank)

- Future governance of Technical Committee
- Profiling activity
- NIBIB contract proposal

Profiling

- Activity is complementary with SNM activity in this area. SNM is working to optimize
 tools that exist now; RSNA is working with vendors to develop better next-generation
 tools. Should strive to avoid redundant activities.
- Profile will be followed by groundwork experiments to substantiate claims, both retrospectively and prospectively. Profile can serve as checklist to present to vendors.
- The clinical context piece provided by Dr Frank addresses the *delta* (possibly 10% for pharma or 25% for clinical relevance, although this is defined in part by the performance of the drug) and *sigma*
- Discussion of scope of QIBA and Technical Committees; suggestion to focus pragmatically on technical areas; avoid duplication of work that may be better addressed by efforts like NCI guidelines
- Mr Buckler agreed to compile first draft of FDG-PET/CT Profile using UPICT/VolCT template; will load on wiki and encourage group comment

Technical Committee activities

- Related to quality control, software versioning and calibration, two issues:
 - Make a list for vendors to fulfill in future
 - Determine how to assist future environment of scanning
- AAPM coming out soon with procedure to be compared with NEMA procedure; vendors and physicists will be asked to review
- Suggestion to write abstract or publish to increase visibility
- For proposed "roadshow" with vendors for Dr Sullivan and Mr Buckler, suggestion to start with 3rd-party vendor like MIMvista
- Consider Technical Committee face-to-face meeting at 2009 World Molecular Imaging Congress, September 23-26, 2009, Montreal, Canada. Drs. Shao, and Kinahan and Mr Christian not planning to attend
- Consider RSNA convening coalition meeting re FDG-PET with SNM, CALGB, ACRIN, QIBA, ASTRO, EORTC, UK cancer research, NIST, etc.
- Consider meeting with vendors at next SNM 2010 annual mtg, Jun 5- Jun 9, 2010, Salt Lake City, Utah. SNM annual meeting is better venue because exhibitor turnout is not as high at Mid-Winter Educational Symposium (Albuquerque, January 28-31, 2010)

Prepare for progress reporting at RSNA 2009

NIBIB proposal

 Subcommittee chairs and Dr Frank will supply materials for Mr Buckler re. clinical context and research plans with resources needed

Governance

 Because of other responsibilities, Dr Frank discussed need for assistance with volunteer governance for the committee

Next steps

- Subcommittee profiles/claims, ICL logistics in trial conduct, data acquisition, collection and analysis (Eric Perlman's contribution from RadPharm) and FDG-PET/CT imaging protocol from Dr Boellaard should be delivered to Mr Buckler for inclusion in draft Profile
- For NIBIB proposal and future planning, subcommittee chairs should submit updated research plan with specific next steps and resources needed (e.g. Dr Kinahan's proposal of SuV quantitation and DRO)
- Look into feasibility of suggested meetings:
 - Technical Committee face-to-face meeting at 2009 World Molecular Imaging Congress, September 23-26, 2009, Montreal, Canada.
 - Coalition meeting re FDG-PET with SNM, CALGB, ACRIN, QIBA, ASTRO, EORTC, UK cancer research, NIST, etc.
 - Vendor meeting at next SNM 2010 annual mtg, Jun 5- Jun 9, 2010, Salt Lake City, Utah.
- Begin planning for direct advocacy meetings between RSNA staff and decision-makers among relevant vendor companies
- Prepare for progress reporting at RSNA 2009